A217330 Share Price Performance
₩2,735.00
-5375.00 (-66.28%)
Price ₩2,735.00
Share Price₩2,735.00
A217330 Community Narratives
There are no narratives available yet.
Recent A217330 News & Updates
No updates
Cytogen, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -720.08
- Gross Margin
- 25.99%
- Net Profit Margin
- -105.73%
- Debt/Equity Ratio
- 29.6%
Cytogen, Inc. Competitors
About A217330
- Founded
- 2010
- Employees
- 50
- CEO
- WebsiteView website
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea.
South Korean Market Performance
- 7 Days: -1.6%
- 3 Months: 21.9%
- 1 Year: 21.3%
- Year to Date: 30.7%
Over the last 7 days, the market has dropped 1.6%, driven by a decline of 3.6% in the Information Technology sector. In the last year, the market is actually up 21%. Earnings are forecast to grow by 22% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading